Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Julia Etchin, PhD, Alla Berezovskaya, Amy Saur Conway, Weihsu Claire Chen, PhD, Erkan Baloglu, PhD, Yosef Landesman, PhD, William Senapedis, PhD, Joel Ellis, PhD, Dilara McCauley, PhD, Richard M. Stone, MD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Michael Kauffman, Sharon Shacham, Jean C.Y. Wang, MDPhD, A. Thomas Look, MD

Blood (2015) 126 (23): 326.

https://doi.org/10.1182/blood.V126.23.326.326

Published: 2015

Journal Articles

Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells

Julia Etchin, PhD, Bonnie Thi Le, M.S., Alex Kentsis, MD PhD, Marc R Mansour, MDPhD, Alla Berezovskaya, B.S., Richard M. Stone, MD, Ilene Galinsky, RNP, Daniel J. DeAngelo, MDPhD, Dilara McCauley, PhD, Michael Kauffman, MD PhD, Sharon Shacham, PhDMBA, Jean C.Y. Wang, MDPhD, Andrew L Kung, MD PhD, A. Thomas Look, MD

Blood (2014) 124 (21): 995.

https://doi.org/10.1182/blood.V124.21.995.995

Published: 2014

Journal Articles

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

Blood (2014) 124 (21): 396.

https://doi.org/10.1182/blood.V124.21.396.396

Published: 2014

Journal Articles

In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs

Marsha Crochiere, PhD, Boris Klebanov, M.A., MsC, Erkan Baloglu, PhD, Ori Kalid, PhD, Trinayan Kashyap, MSc, William Senapedis, PhD, Diego del Alamo, BS, Tami Rashal, MD, Sharon Tamir, PhD, Dilara McCauley, PhD, Robert Carlson, PhD, Michael Savona, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhDMBA, Yosef Landesman, PhD

Blood (2014) 124 (21): 5196.

https://doi.org/10.1182/blood.V124.21.5196.5196

Published: 2014

Journal Articles

Anti-Myeloma Activity of Combined Inhibition of the Proteasome with Carfilzomib (CFZ) and XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330) Via a Novel Mechanism of Intracellular Activation of Caspase 10-Dependent Apoptosis

Shaun Rosebeck, PhD, Mattina Alonge, MS, Jagoda Jasielec, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 3443.

https://doi.org/10.1182/blood.V124.21.3443.3443

Published: 2014

Journal Articles

Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies

William Senapedis, PhD, Ryan George, PhD, Dilara McCauley, PhD, Joel Ellis, PhD, Marsha Crochiere, PhD, Michael Savona, MD, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Erkan Baloglu, PhD

Blood (2014) 124 (21): 2208.

https://doi.org/10.1182/blood.V124.21.2208.2208

Published: 2014

Journal Articles

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

Blood (2013) 122 (21): 1440.

https://doi.org/10.1182/blood.V122.21.1440.1440

Published: 2013

Journal Articles

Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML “primagrafts,” Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells

Julia Etchin, PhD, Bonnie Thi Le, M.S., Alex Kentsis, MD, PhD, Richard M. Stone, MD, Dilara McCauley, PhD, Michael Kauffman, MD, PhD, Sharon Shacham, PhD, MBA, Jean C.Y. Wang, MD PhD, Andrew L Kung, MD, PhD, A. Thomas Look, MD

Blood (2013) 122 (21): 3932.

https://doi.org/10.1182/blood.V122.21.3932.3932

Published: 2013

Journal Articles

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

Blood (2013) 122 (21): 1942.

https://doi.org/10.1182/blood.V122.21.1942.1942

Published: 2013

Journal Articles

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Blood (2013) 122 (21): 90.

https://doi.org/10.1182/blood.V122.21.90.90

Published: 2013

Journal Articles

Evaluation Of The Novel, Orally Bioavailable Selective Inhibitor Of Nuclear Export (SINE) Verdinexor (KPT-335) In Spontaneous Canine Cancer: Results Of Phase I and Phase II Clinical Trials

Cheryl London, DVM, PhD, Luis feo Bernabe, DVM, Sandra Barnard, BVSc, William Kisseberth, DVM, PhD, Antonella Borgatti, DVM, Michael Henson, DVM, Heather Wilson, DVM, Kiersten Jensen, MS, Daisuke Ito, DVM PhD, Jaime Modiano, DVM PhD, Misty Bear, MS, Michael Pennell, Jean-Richard Saint-Martin, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD

Blood (2013) 122 (21): 5149.

https://doi.org/10.1182/blood.V122.21.5149.5149

Published: 2013

Journal Articles

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Mattina M. Alonge, Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Sean P Maxwell, Stephanie J Kraftson, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 279.

https://doi.org/10.1182/blood.V122.21.279.279

Published: 2013

Journal Articles

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

Michael P. Rettig, PhD, Matthew Holt, Julie Prior, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 237.

https://doi.org/10.1182/blood.V122.21.237.237

Published: 2013

Journal Articles

Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin's Lymphomas (NHL)

Sharon Shacham, PhD MBA, Sandra Barnard, BVSc, William Kisseberth, DVM, PhD, Daisuke Ito, DVM PhD, Kiersten Jensen, Antonella Borgotti, DVM MS, Michael Henson, DVM PhD, Heather Wilson, DVM, Dilara McCauley, PhD, Jaime Modiano, DVM PhD, Michael Kauffman, MD, PhD, Cheryl London, DVM PhD

Blood (2012) 120 (21): 161.

https://doi.org/10.1182/blood.V120.21.161.161

Published: 2012

Journal Articles

CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis

Blood (2012) 120 (21): 326.

https://doi.org/10.1182/blood.V120.21.326.326

Published: 2012

Journal Articles

Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276

Jessica Schmidt, Esteban Braggio, Ph.D., Marta Chesi, PhD, Jan Egan, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Stephen Palmer, Victoria Garbitt, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Leif Bergsagel, MD, Keith Stewart, MD

Blood (2012) 120 (21): 573.

https://doi.org/10.1182/blood.V120.21.573.573

Published: 2012

Journal Articles

Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL.

Rosa Lapalombella, PhD, Virginia Goettl, Katie Williams, Larissa Tangeman, Shruti Jha, Jason A Dubovsky, Ph.D, Danielle L Chappell, Amy J Johnson, PhD, Vincent Sandanayaka, Sharon Shechter, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 2452.

https://doi.org/10.1182/blood.V120.21.2452.2452

Published: 2012

Journal Articles

Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma

Kejie Zhang, MD, PhD, Lan V Pham, PhD, Liang Zhang, MD, PhD, Archito T. Tamayo, MS, Zhishuo Ou, MD, Dilara McCauley, PhD, Sharon Shacham, PhD, Michael Kauffman, MD, PhD, Richard J. Ford, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 2734.

https://doi.org/10.1182/blood.V118.21.2734.2734

Published: 2011

Journal Articles

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Sun-Young Kong, MD, PhD, Yosef Landesman, PhD, Jana Jakubikova, PhD, Michael A. Sellitto, Antonia Cagnetta, MD, Michele Cea, MD, Michelle C. Chen, Francesca Cottini, MD, Douglas W. McMillin, PhD, Chirag Acharya, MD, William Senapedis, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, Jean-Richard Saint-Martin, BS, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2011) 118 (21): 2913.

https://doi.org/10.1182/blood.V118.21.2913.2913

Published: 2011

Journal Articles

CRM1 Is Highly Expressed in Myeloma Plasma Cells and Its Inhibition by KPT-SINE Induces Cytotoxicity by Increasing p53 in the Nucleus of Multiple Myeloma (MM) Cells

Malathi Kandarpa, PhD, Stephanie J Kraftson, Sean P Maxwell, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, Andrzej J Jakubowiak, MD, PhD

Blood (2011) 118 (21): 1852.

https://doi.org/10.1182/blood.V118.21.1852.1852

Published: 2011

NARROW

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs

Anti-Myeloma Activity of Combined Inhibition of the Proteasome with Carfilzomib (CFZ) and XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330) Via a Novel Mechanism of Intracellular Activation of Caspase 10-Dependent Apoptosis

Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML “primagrafts,” Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Evaluation Of The Novel, Orally Bioavailable Selective Inhibitor Of Nuclear Export (SINE) Verdinexor (KPT-335) In Spontaneous Canine Cancer: Results Of Phase I and Phase II Clinical Trials

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin's Lymphomas (NHL)

CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis

Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276

Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL.

Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

CRM1 Is Highly Expressed in Myeloma Plasma Cells and Its Inhibition by KPT-SINE Induces Cytotoxicity by Increasing p53 in the Nucleus of Multiple Myeloma (MM) Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only